0001193125-18-275855.txt : 20180918 0001193125-18-275855.hdr.sgml : 20180918 20180918080135 ACCESSION NUMBER: 0001193125-18-275855 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180918 FILED AS OF DATE: 20180918 DATE AS OF CHANGE: 20180918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 181074655 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 6-K 1 d626216d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of September, 2018

Commission File Number 001-38079

 

 

UROGEN PHARMA LTD.

(Translation of registrant’s name into English)

 

 

9 Ha’Ta’asiya Street

Ra’anana 4365007, Israel

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒             Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

From September 13, 2018 to September 14, 2018, Ron Bentsur, UroGen Pharma Ltd.’s Chief Executive Officer, purchased 4,430 ordinary shares, par value NIS 0.01 per share, of the company in open market transactions at an average price of $45.06 per share.

On September 17, 2018, Peter Pfreundschuh, UroGen Pharma Ltd.’s Chief Financial Officer, purchased 1,000 ordinary shares, par value NIS 0.01 per share, of the company in open market transactions at an average price of $45.73 per share.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    UROGEN PHARMA LTD.
September 18, 2018     By:  

/s/Ron Bentsur

      Ron Bentsur
      Chief Executive Officer